Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRILAT versus LEXXEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRILAT versus LEXXEL.
ENALAPRILAT vs LEXXEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and cardiac workload.
LEXXEL is a combination of felodipine, a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium reabsorption.
1.25 mg IV over 5 minutes every 6 hours; may increase to 5 mg IV every 6 hours if needed.
1 tablet (felodipine 5 mg / enalapril 5 mg) orally once daily, may increase to 2 tablets once daily after 2-4 weeks if needed.
None Documented
None Documented
Clinical Note
moderateEnalaprilat + Benzydamine
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benzydamine."
Clinical Note
moderateEnalaprilat + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat."
Clinical Note
moderateEnalaprilat + Droxicam
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam."
Clinical Note
moderateEnalaprilat + Loxoprofen
Terminal half-life: 35 hours (prolonged in renal impairment; accumulates with CrCl <30 mL/min)
Enalapril: ~1.3 hours; Enalaprilat: terminal half-life ~35-38 hours, with multiple-dose accumulation half-life ~11 hours; effective half-life for ACE inhibition ~24 hours.
Renal: 60-80% unchanged; biliary/fecal: minimal (<10%)
Renal: ~35-50% as unchanged drug (enalaprilat), biliary/fecal: ~15-30% as metabolites and unchanged drug; total renal elimination of enalaprilat accounts for ~60-80% of dose.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor + Calcium Channel Blocker
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen."